NCT05967416View on ClinicalTrials.gov

Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 17, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions
Refractory Non-Hodgkin LymphomaRelapsed Non-Hodgkin Lymphoma
Interventions
BIOLOGICAL

SIRPant-M

Autologous activated macrophage cell therapy manufactured from peripheral blood mononuclear cells given by intratumoral injection

RADIATION

External-beam radiotherapy (XRT)

Radiotherapy given by external beam to the IT-injected lesion only

Trial Locations (3)

77030

RECRUITING

MD Anderson Cancer Center, Houston

91010

RECRUITING

City of Hope, Duarte

07601

RECRUITING

Hackensack University Medical Center, Hackensack

All Listed Sponsors
lead

SIRPant Immunotherapeutics, Inc.

INDUSTRY